Revvity forecasts 2026 profit, revenue above estimates after blowout fourth quarter

Group 1 - Revvity exceeded fourth-quarter estimates and forecasts for 2026 revenue and profit, driven by strength in its diagnostics business despite ongoing weakness in academic research funding [1][2] - The company anticipates adjusted profit per share for 2026 to be between $5.35 and $5.45, slightly above analysts' estimates of $5.32 [2] - Revvity projects annual sales for 2026 to be between $2.96 billion and $2.99 billion, surpassing the estimated $2.93 billion [2] Group 2 - Revvity's diagnostics unit achieved 7% organic growth, generating revenue of $390.1 million, significantly exceeding the $377.7 million forecasted by analysts [3] - The life sciences unit reported revenue of $382 million, slightly below the estimated $385.6 million [4] - Quarterly adjusted profit was $1.70 per share, surpassing the expected $1.55 per share, with total quarterly sales reaching $772.1 million, exceeding estimates of $761.3 million [4]